Sign In
Buy ILMN
$170.93
+8.38 (+5.16%)
At Close: Jun 03, 2026
ILMN Stock Set to Gain From Expansion of TruSight Oncology Portfolio
08:11am, Wednesday, 20'th Nov 2024
Illumina's new TSO 500 v2 assay aims to enable CGP of tumors, bolstering its TruSight Oncology portfolio.
Illumina announces expansion of TruSight Oncology portfolio
09:15am, Tuesday, 19'th Nov 2024
The latest solution to enable comprehensive genomic profiling of tumors will be presented at the annual meeting of the Association of Molecular Pathology Customer-led research and presentations at
Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term
10:51am, Monday, 11'th Nov 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Interpreting Illumina (ILMN) International Revenue Trends
10:16am, Thursday, 07'th Nov 2024
Explore how Illumina's (ILMN) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Illumina To Webcast Upcoming Investor Conferences
04:05pm, Wednesday, 06'th Nov 2024
SAN DIEGO , Nov. 6, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conferences: Wolfe Research 2024 Healthcare Confe
Illumina: Q3 Confirms Improving Fundamentals
01:12pm, Tuesday, 05'th Nov 2024
Illumina is the leader in the undisputed Next Generation Sequencing market. Grail divestment is behind, enabling a margin expansion and fueling a more robust cash flow generation. The stock was down a
ILMN Q3 Earnings Top, '24 Sales View Down, Stock Dips in Aftermarket
10:20am, Tuesday, 05'th Nov 2024
Illumina's third- quarter revenues from the consumables business show robust growth, offset by the declining instruments business.
Illumina (ILMN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
08:31pm, Monday, 04'th Nov 2024
The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street est
Illumina, Inc. (ILMN) Q3 2024 Earnings Call Transcript
08:09pm, Monday, 04'th Nov 2024
Illumina, Inc. (NASDAQ:ILMN ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Corporate Participants Salli Schwartz - Vice President of Investor Relations Jacob Thaysen - Chief Executive
Illumina (ILMN) Tops Q3 Earnings and Revenue Estimates
06:56pm, Monday, 04'th Nov 2024
Illumina (ILMN) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $0.87 per share. This compares to earnings of $0.33 per share a year ago.
EARNINGS ALERT: ILMN
04:47pm, Monday, 04'th Nov 2024
Illumina (ILMN) is trading down guiding a 3% decline in revenue. George Tsilis believes the company is still notable despite the market's reaction.
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2024
04:05pm, Monday, 04'th Nov 2024
Core Illumina revenue of $1.1 billion for Q3 2024, down 2% from Q3 2023 and on a constant currency basis Core Illumina GAAP operating margin of 68.6% and non-GAAP operating margin of 22.6% for Q3 2024
Illumina to preview newest innovations in NGS and multiomic technologies at the American Society of Human Genetics Annual Meeting
09:15am, Thursday, 31'st Oct 2024
New, groundbreaking technology delivers Illumina's most comprehensive genome yet ; early results from Broad Clinical Labs demonstrate a highly simplified workflow , ultra-long phasing, high-resolution
What Analyst Projections for Key Metrics Reveal About Illumina (ILMN) Q3 Earnings
10:20am, Wednesday, 30'th Oct 2024
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Illumina (ILMN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the q
Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:05am, Monday, 28'th Oct 2024
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
